Eli Lilly (LLY)
(Delayed Data from NYSE)
$865.00 USD
+15.01 (1.77%)
Updated Jun 10, 2024 04:01 PM ET
After-Market: $875.00 +10.00 (1.16%) 5:08 PM ET
3-Hold of 5 3
D Value B Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$865.00 USD
+15.01 (1.77%)
Updated Jun 10, 2024 04:01 PM ET
After-Market: $875.00 +10.00 (1.16%) 5:08 PM ET
3-Hold of 5 3
D Value B Growth F Momentum C VGM
Zacks News
What's in the Cards for IDEX (IEX) this Earnings Season?
by Zacks Equity Research
IDEX Corporation (IEX) is scheduled to report first-quarter 2017 results after the closing bell on Apr 19.
Profit from These 5 Sturdy Stocks as Fear Grips Markets
by Tirthankar Chakraborty
Wall Street's fear gauge is breaking out higher as geopolitical risks heat up after the U.S. opted for 'Mother of All Bombs'.
J&J (JNJ) to Kick Off Pharma Q1 Earnings: Will it Beat?
by Zacks Equity Research
We expect Johnson & Johnson (JNJ), a healthcare bellwether, to beat expectations when it reports first-quarter 2017 results on Apr 18, before the opening bell.
What's in the Cards for Omnicom (OMC) this Earnings Season?
by Zacks Equity Research
Omnicom Group Inc. (OMC) is scheduled to report first-quarter 2017 results before the opening bell on Apr 18.
ANTH's (ANTH) Blisibimod Completes Dosing in Phase III Study
by Zacks Equity Research
Anthera Pharmaceuticals, Inc. (ANTH) recently announced the completion of dosing in a phase II study, BRIGHT-SC. The study evaluated key pipeline candidate blisibimod for treatment of patients with IgA nephropathy (IgAN).
Merck's Bid to Add Cardiovascular Data on Januvia Label Fails
by Zacks Equity Research
Merck announced that the FDA has denied approval to include cardiovascular outcomes data on the labels of its diabetes drug, Januvia (sitagliptin) and other medicines containing Januvia.
Infinity Pharmaceuticals Focuses on Lead Candidate IPI-549
by Zacks Equity Research
We issued an updated report on Infinity Pharmaceuticals, Inc. (INFI) on Apr 7.
Novartis (NVS) In-Licenses Ophthalmic Drug from Lubris LLC
by Zacks Equity Research
Novartis AG (NVS) recently announced that it has exercised an option to in-license ECF843 for ophthalmic indications worldwide from Lubris LLC.
AbbVie/J&J's Imbruvica Label Expansion Filing Accepted by FDA
by Zacks Equity Research
AbbVie Inc. (ABBV) and partner Janssen, Johnson & Johnson's (JNJ) pharmaceuticals subsidiary, announced that a supplemental new drug application (sNDA) for their cancer drug Imbruvica has been accepted for review by the FDA.
5 Reasons to Invest in Eli Lilly (LLY) Stock Right Now
by Zacks Equity Research
Lily carries a Zacks Rank #2 (Buy).
Novartis' Tafinlar, Mekinist Get EU Approval for NSCLC
by Zacks Equity Research
Novartis AG (NVS) recently announced that the European Commission has approved Tafinlar in combination with Mekinist for the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer (NSCLC).
United Therapeutics Tanks, Remodulin Pump Launch Delayed
by Zacks Equity Research
United Therapeutics Corporation (UTHR) shares plunged around 9% on Monday after the company announced that regulatory issues will delay the planned U.S. launch of RemoSynch - an implantable pump for delivering Remodulin
4 FDA Decisions to Watch Out for in Apr 2017
by Arpita Dutt
Companies like BioMarin (BMRN), Roche and Takeda among others have regulatory decisions scheduled for this month.
Why Equal Weighted Mutual Funds Scoring Over Index Funds
by Zacks Equity Research
Investors interested in maintaining a diversified portfolio might consider investing in equal-weight funds.
AstraZeneca Stock Rising in '17: What's Working in its Favor?
by Zacks Equity Research
Shares of London-based pharma giant, AstraZeneca plc (AZN) have risen 13.4% this year so far, while the Zacks classified Large-Cap Pharma industry increased 6.4%.
Merck Closes Acquisition of Controlling Stake in Vallee S.A
by Zacks Equity Research
Merck & Co., Inc. (MRK) has completed the previously announced acquisition of a controlling stake in Vallee S.A., a leading privately held producer of animal health products in Brazil.
Novartis' Acute Heart Failure Drug Fails in Late-Stage Study
by Zacks Equity Research
Novartis AG (NVS) recently suffered a setback on the announcement of disappointing data from a phase III study, RELAX-AHF-2, on pipeline candidate serelaxin (RLX030).
Lilly's Breast Cancer Combo Drug Phase III Results Positive
by Zacks Equity Research
Eli Lilly and Company (LLY) recently announced that a phase III combination study evaluating its pipeline candidate abemaciclib in advanced breast cancer, met the primary endpoint of progression-free survival (PFS).
Novartis (NVS) Announces Positive Data on Heart Failure Drug
by Zacks Equity Research
Novartis AG (NVS) recently announced results of a new post-hoc analysis from the PARADIGM-HF study on heart failure drug Entresto.
What are Sanofi's (SNY) Strengths and Challenges in 2017?
by Zacks Equity Research
We issued an updated research report on Sanofi (SNY) on Mar 16, 2017.
Novo Nordisk's Diabetes Unit Strong; Generic Pressure Stays
by Zacks Equity Research
We issued an updated research report on Novo Nordisk (NVO) on Mar 9, 2017.
How Incyte Stock Became a Bull Market Star for Biotech Investors
by Arpita Dutt
Incyte (INCY) tops the list of stocks that enjoyed a stupendous run in the last 8 years.
Merck/Pfizer's Diabetes Drug Accepted for Review by FDA, EMA
by Zacks Equity Research
Merck & Co., Inc. (MRK) and partner Pfizer, Inc. (PFE) announced that the FDA has accepted its new drug applications (NDA) for ertugliflozin as a monotherapy as well as two fixed-dose combination tablets.
Trump Tweet on Drug Pricing Hits Biotech and Pharma ETFs
by Sweta Killa
President Donald Trump March 7 tweet on increasing competition and lowering drug prices sent fresh shockwaves across the industry.
Eli Lilly's Taltz Shows Better Efficacy than J&J's Stelara
by Zacks Equity Research
Eli Lilly and Company (LLY) announced superior efficacy in a head-to-head study evaluating its marketed drug, Taltz (ixekizumab) versus with Johnson & Johnson???s Stelara (ustekinumab) in patients with moderate-to-severe plaque.